Human Insulin Market By Product Type, By Indication By Type of Insulin By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
인간 인슐린 시장
인간 인슐린 시장은 2023년 171억 달러로 평가되며, 2024-2033년 연평균 3.4% 성장하여 2033년에는 240억 달러에 달할 것으로 예상됩니다.
인간 인슐린은 천연 펩타이드 호르몬의 합성 모방품으로 실험실에서 대장균에서 합성됩니다. 인슐린은 단시간 작용하는 일반형과 신경 프로타민 헤게돈 인슐린으로 알려진 중간형 인슐린으로 나뉩니다. 인간 인슐린은 체내에서 자연적으로 생성되는 인슐린을 대체하여 혈액 내 포도당 수치를 조절합니다.
인간 인슐린 시장의 주요 촉진요인은 전 세계 당뇨병 유병률의 증가입니다. 또한, 인간 인슐린은 동물성 인슐린에 비해 높은 효능과 최소한의 알레르기 반응 위험으로 인해 환자와 개업의들의 수요가 급증하고 있습니다. 최근 인간 인슐린 시장의 최신 트렌드는 동등한 효능과 높은 비용 대비 효과로 인해 환자들이 바이오시밀러 제품을 선호하고 있다는 점입니다.
그러나 경구용 약물과 GLP-1 수용체 작용제를 포함한 비인슐린 주사제와 같은 다른 대체품의 존재는 인간 인슐린에 큰 경쟁을 제공하고 있습니다. 또한, 인간 인슐린의 시장 출시는 전임상, 임상시험, 시판 후 안전성 모니터링 등 다양한 단계의 규제 승인 절차에 시간이 걸리기 때문에 복잡하고 시간이 많이 소요되는 과정입니다. 이로 인해 단백질의 출시가 지연되고 시장 개척에 제약이 따릅니다. 반면, AI 및 머신러닝과 같은 데이터 기반 접근 방식의 통합은 생산 매개변수 최적화 및 제품 수율 예측을 통해 생산 효율을 가속화할 수 있을 것으로 기대됩니다.
부문별 리뷰
인간 인슐린 시장은 제품 유형, 적응증, 인슐린 유형, 유통 채널, 지역으로 구분됩니다. 제품 유형별로 시장은 펜, 주사기, 기타로 나뉩니다. 적응증에 따라 제1형 당뇨병, 제2형 당뇨병, 임신성 당뇨병으로 분류됩니다. 인슐린 유형에 따라 속효성 인슐린, 단시간 작용 인슐린, 중간 작용 인슐린, 기타로 나뉩니다. 유통 채널에 따라 병원 약국, 드럭스토어 및 소매 약국, 온라인 공급업체로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.
주요 조사 결과
제품 유형별로는 2023년 펜 부문이 시장을 장악했습니다.
적응증별로는 제1형 당뇨병 부문이 2023년 시장에서 가장 높은 지위를 차지했습니다.
인슐린 유형별로는 속효성 인슐린 부문이 2023년 높은 시장 점유율을 차지했습니다.
유통 채널별로는 드럭스토어 및 소매 약국 부문이 2023년 가장 높은 점유율을 차지했습니다.
지역별로는 북미가 2023년 가장 높은 수익을 올렸습니다.
이 보고서는 사용자 정의가 가능합니다.
- 규제 가이드라인
- 고객의 관심사에 따른 기업 프로파일 추가
- 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
- 기업 개요 확대 목록
- 과거 시장 데이터
- 주요 진입기업 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)
목차
제1장 소개
제2장 주요 요약
제3장 시장 상황
- 시장 정의와 범위
- 주요 조사 결과
- Porter's Five Forces 분석
- 시장 역학
제4장 제품 유형별 인간 인슐린 시장
제5장 인간 인슐린 시장 : 적응증별
- 시장 개요
- 1형 당뇨병
- 2형 당뇨병
- 임신 당뇨병
제6장 인간 인슐린 시장 : 인슐린 유형별
- 시장 개요
- 속효성 인슐린
- 단시간 작용형 인슐린
- 중간 작용형 인슐린
- 기타
제7장 인간 인슐린 시장 : 유통 채널별
- 시장 개요
- 병원 약국
- 드럭스토어와 소매 약국
- 온라인 프로바이더
제8장 인간 인슐린 시장 : 지역별
- 시장 개요
- 북미
- 주요 시장 동향과 기회
- 미국의 인간 인슐린 시장
- 캐나다의 인간 인슐린 시장
- 멕시코의 인간 인슐린 시장
- 유럽
- 주요 시장 동향과 기회
- 독일의 인간 인슐린 시장
- 프랑스의 인간 인슐린 시장
- 영국의 인간 인슐린 시장
- 이탈리아의 인간 인슐린 시장
- 스페인의 인간 인슐린 시장
- 기타 유럽의 인간 인슐린 시장
- 아시아태평양
- 주요 시장 동향과 기회
- 일본의 인간 인슐린 시장
- 중국의 인간 인슐린 시장
- 인도의 인간 인슐린 시장
- 호주의 인간 인슐린 시장
- 한국의 인간 인슐린 시장
- 기타 아시아태평양의 인간 인슐린 시장
- 라틴아메리카, 중동 및 아프리카
- 주요 시장 동향과 기회
- 브라질의 인간 인슐린 시장
- 사우디아라비아의 인간 인슐린 시장
- 남아프리카공화국의 인간 인슐린 시장
- 기타 라틴아메리카, 중동 및 아프리카 인간 인슐린 시장
제9장 경쟁 상황
- 소개
- 주요 성공 전략
- 주요 10개 기업 제품 매핑
- 경쟁 대시보드
- 경쟁 히트맵
- 주요 기업의 포지셔닝(2023년)
제10장 기업 개요
- Eli Lilly And Company
- Sanofi
- Novo Nordisk A/S
- Pfizer
- Biocon
- Wockhardt
- MannKind Corporation
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Medtronic
- Lupin
ksm
Human Insulin Market
The human insulin market was valued at $17.1 billion in 2023 and is projected to reach $24.0 billion by 2033, growing at a CAGR of 3.4% from 2024 to 2033.
Human insulin is a synthetic mimic of the natural peptide hormone, which is synthesized in laboratory settings inside E. coli bacteria. It exists in two forms: a short-acting regular form and an intermediate-acting form known as neural protamine Hagedorn insulin. Human insulin replaces the naturally produced insulin inside the body and regulates the glucose levels in the blood.
A key driver of the human insulin market is increase in the prevalence of diabetes globally. In addition, human insulin is experiencing a surge in demand from patients and medical practitioners as compared to animal insulin owing to its high efficacy and minimal risk of allergic reactions. The latest trend in the human insulin market is the inclination of patients toward biosimilar products owing to their comparable efficacy and high cost-effectiveness.
However, the presence of other alternatives such as oral medications and non-insulin injectables, including GLP-1 receptor agonists, offers a significant competition to human insulin. Moreover, the introduction of human insulin into the market is a complex & time-consuming process due to the lengthy regulatory approval procedure at different stages, which include pre-clinical stages, clinical trials, and post-market safety monitoring. This delays the availability of the protein, thereby limiting the development of the market. On the contrary, the integration of data-driven approaches such as AI and machine learning is expected to speed up production efficiency by optimizing the production parameters and predicting product yields.
Segment Review
The human insulin market is segmented into product type, indication, type of insulin, distribution channel, and region. On the basis of product type, the market is divided into pens, syringes, and others. As per indication, it is classified into type 1 diabetes, type 2 diabetes, and gestational diabetes. Depending on type of insulin, it is categorized into rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and others. According to distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of product type, the pens segment dominated the market in 2023.
As per indication, the type-1 diabetes segment acquired high stakes in the market in 2023.
Depending on type of insulin, the rapid-acting insulin segment garnered a high market share in 2023.
According to distribution channel, the drug stores & retail pharmacies segment was the highest shareholder in 2023.
Region wise, North America was the highest revenue generator in 2023.
Competition Analysis
The major players operating in the global human insulin market include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Pfizer, Biocon, Wockhardt, MannKind Corporation, Tonghua Dongbao Pharmaceutical Co., Ltd., Medtronic, and Lupin. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Product Type
By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
By Type Of Insulin
- Rapid-acting insulin
- Short-acting insulin
- Intermediate-acting insulin
- Others
By Distribution Channel
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players:
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- Pfizer
- Biocon
- Wockhardt
- MannKind Corporation
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Medtronic
- Lupin
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
CHAPTER 4: HUMAN INSULIN MARKET, BY PRODUCT TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Product Type
- 4.2. Pens
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Syringes
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Others
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
CHAPTER 5: HUMAN INSULIN MARKET, BY INDICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Indication
- 5.2. Type 1 Diabetes
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Type 2 Diabetes
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Gestational Diabetes
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
CHAPTER 6: HUMAN INSULIN MARKET, BY TYPE OF INSULIN
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Type of Insulin
- 6.2. Rapid-acting Insulin
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Short-acting Insulin
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Intermediate-acting Insulin
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- 6.5. Others
- 6.5.1. Key Market Trends, Growth Factors and Opportunities
- 6.5.2. Market Size and Forecast, By Region
- 6.5.3. Market Share Analysis, By Country
CHAPTER 7: HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Distribution Channel
- 7.2. Hospital Pharmacies
- 7.2.1. Key Market Trends, Growth Factors and Opportunities
- 7.2.2. Market Size and Forecast, By Region
- 7.2.3. Market Share Analysis, By Country
- 7.3. Drug Stores And Retail Pharmacies
- 7.3.1. Key Market Trends, Growth Factors and Opportunities
- 7.3.2. Market Size and Forecast, By Region
- 7.3.3. Market Share Analysis, By Country
- 7.4. Online Providers
- 7.4.1. Key Market Trends, Growth Factors and Opportunities
- 7.4.2. Market Size and Forecast, By Region
- 7.4.3. Market Share Analysis, By Country
CHAPTER 8: HUMAN INSULIN MARKET, BY REGION
- 8.1. Market Overview
- 8.1.1 Market Size and Forecast, By Region
- 8.2. North America
- 8.2.1. Key Market Trends and Opportunities
- 8.2.2. Market Size and Forecast, By Product Type
- 8.2.3. Market Size and Forecast, By Indication
- 8.2.4. Market Size and Forecast, By Type of Insulin
- 8.2.5. Market Size and Forecast, By Distribution Channel
- 8.2.6. Market Size and Forecast, By Country
- 8.2.7. U.S. Human Insulin Market
- 8.2.7.1. Market Size and Forecast, By Product Type
- 8.2.7.2. Market Size and Forecast, By Indication
- 8.2.7.3. Market Size and Forecast, By Type of Insulin
- 8.2.7.4. Market Size and Forecast, By Distribution Channel
- 8.2.8. Canada Human Insulin Market
- 8.2.8.1. Market Size and Forecast, By Product Type
- 8.2.8.2. Market Size and Forecast, By Indication
- 8.2.8.3. Market Size and Forecast, By Type of Insulin
- 8.2.8.4. Market Size and Forecast, By Distribution Channel
- 8.2.9. Mexico Human Insulin Market
- 8.2.9.1. Market Size and Forecast, By Product Type
- 8.2.9.2. Market Size and Forecast, By Indication
- 8.2.9.3. Market Size and Forecast, By Type of Insulin
- 8.2.9.4. Market Size and Forecast, By Distribution Channel
- 8.3. Europe
- 8.3.1. Key Market Trends and Opportunities
- 8.3.2. Market Size and Forecast, By Product Type
- 8.3.3. Market Size and Forecast, By Indication
- 8.3.4. Market Size and Forecast, By Type of Insulin
- 8.3.5. Market Size and Forecast, By Distribution Channel
- 8.3.6. Market Size and Forecast, By Country
- 8.3.7. Germany Human Insulin Market
- 8.3.7.1. Market Size and Forecast, By Product Type
- 8.3.7.2. Market Size and Forecast, By Indication
- 8.3.7.3. Market Size and Forecast, By Type of Insulin
- 8.3.7.4. Market Size and Forecast, By Distribution Channel
- 8.3.8. France Human Insulin Market
- 8.3.8.1. Market Size and Forecast, By Product Type
- 8.3.8.2. Market Size and Forecast, By Indication
- 8.3.8.3. Market Size and Forecast, By Type of Insulin
- 8.3.8.4. Market Size and Forecast, By Distribution Channel
- 8.3.9. UK Human Insulin Market
- 8.3.9.1. Market Size and Forecast, By Product Type
- 8.3.9.2. Market Size and Forecast, By Indication
- 8.3.9.3. Market Size and Forecast, By Type of Insulin
- 8.3.9.4. Market Size and Forecast, By Distribution Channel
- 8.3.10. Italy Human Insulin Market
- 8.3.10.1. Market Size and Forecast, By Product Type
- 8.3.10.2. Market Size and Forecast, By Indication
- 8.3.10.3. Market Size and Forecast, By Type of Insulin
- 8.3.10.4. Market Size and Forecast, By Distribution Channel
- 8.3.11. Spain Human Insulin Market
- 8.3.11.1. Market Size and Forecast, By Product Type
- 8.3.11.2. Market Size and Forecast, By Indication
- 8.3.11.3. Market Size and Forecast, By Type of Insulin
- 8.3.11.4. Market Size and Forecast, By Distribution Channel
- 8.3.12. Rest of Europe Human Insulin Market
- 8.3.12.1. Market Size and Forecast, By Product Type
- 8.3.12.2. Market Size and Forecast, By Indication
- 8.3.12.3. Market Size and Forecast, By Type of Insulin
- 8.3.12.4. Market Size and Forecast, By Distribution Channel
- 8.4. Asia-Pacific
- 8.4.1. Key Market Trends and Opportunities
- 8.4.2. Market Size and Forecast, By Product Type
- 8.4.3. Market Size and Forecast, By Indication
- 8.4.4. Market Size and Forecast, By Type of Insulin
- 8.4.5. Market Size and Forecast, By Distribution Channel
- 8.4.6. Market Size and Forecast, By Country
- 8.4.7. Japan Human Insulin Market
- 8.4.7.1. Market Size and Forecast, By Product Type
- 8.4.7.2. Market Size and Forecast, By Indication
- 8.4.7.3. Market Size and Forecast, By Type of Insulin
- 8.4.7.4. Market Size and Forecast, By Distribution Channel
- 8.4.8. China Human Insulin Market
- 8.4.8.1. Market Size and Forecast, By Product Type
- 8.4.8.2. Market Size and Forecast, By Indication
- 8.4.8.3. Market Size and Forecast, By Type of Insulin
- 8.4.8.4. Market Size and Forecast, By Distribution Channel
- 8.4.9. India Human Insulin Market
- 8.4.9.1. Market Size and Forecast, By Product Type
- 8.4.9.2. Market Size and Forecast, By Indication
- 8.4.9.3. Market Size and Forecast, By Type of Insulin
- 8.4.9.4. Market Size and Forecast, By Distribution Channel
- 8.4.10. Australia Human Insulin Market
- 8.4.10.1. Market Size and Forecast, By Product Type
- 8.4.10.2. Market Size and Forecast, By Indication
- 8.4.10.3. Market Size and Forecast, By Type of Insulin
- 8.4.10.4. Market Size and Forecast, By Distribution Channel
- 8.4.11. South Korea Human Insulin Market
- 8.4.11.1. Market Size and Forecast, By Product Type
- 8.4.11.2. Market Size and Forecast, By Indication
- 8.4.11.3. Market Size and Forecast, By Type of Insulin
- 8.4.11.4. Market Size and Forecast, By Distribution Channel
- 8.4.12. Rest of Asia-Pacific Human Insulin Market
- 8.4.12.1. Market Size and Forecast, By Product Type
- 8.4.12.2. Market Size and Forecast, By Indication
- 8.4.12.3. Market Size and Forecast, By Type of Insulin
- 8.4.12.4. Market Size and Forecast, By Distribution Channel
- 8.5. LAMEA
- 8.5.1. Key Market Trends and Opportunities
- 8.5.2. Market Size and Forecast, By Product Type
- 8.5.3. Market Size and Forecast, By Indication
- 8.5.4. Market Size and Forecast, By Type of Insulin
- 8.5.5. Market Size and Forecast, By Distribution Channel
- 8.5.6. Market Size and Forecast, By Country
- 8.5.7. Brazil Human Insulin Market
- 8.5.7.1. Market Size and Forecast, By Product Type
- 8.5.7.2. Market Size and Forecast, By Indication
- 8.5.7.3. Market Size and Forecast, By Type of Insulin
- 8.5.7.4. Market Size and Forecast, By Distribution Channel
- 8.5.8. Saudi Arabia Human Insulin Market
- 8.5.8.1. Market Size and Forecast, By Product Type
- 8.5.8.2. Market Size and Forecast, By Indication
- 8.5.8.3. Market Size and Forecast, By Type of Insulin
- 8.5.8.4. Market Size and Forecast, By Distribution Channel
- 8.5.9. South Africa Human Insulin Market
- 8.5.9.1. Market Size and Forecast, By Product Type
- 8.5.9.2. Market Size and Forecast, By Indication
- 8.5.9.3. Market Size and Forecast, By Type of Insulin
- 8.5.9.4. Market Size and Forecast, By Distribution Channel
- 8.5.10. Rest of LAMEA Human Insulin Market
- 8.5.10.1. Market Size and Forecast, By Product Type
- 8.5.10.2. Market Size and Forecast, By Indication
- 8.5.10.3. Market Size and Forecast, By Type of Insulin
- 8.5.10.4. Market Size and Forecast, By Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
- 9.1. Introduction
- 9.2. Top Winning Strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES
- 10.1. Eli Lilly And Company
- 10.1.1. Company Overview
- 10.1.2. Key Executives
- 10.1.3. Company Snapshot
- 10.1.4. Operating Business Segments
- 10.1.5. Product Portfolio
- 10.1.6. Business Performance
- 10.1.7. Key Strategic Moves and Developments
- 10.2. Sanofi
- 10.2.1. Company Overview
- 10.2.2. Key Executives
- 10.2.3. Company Snapshot
- 10.2.4. Operating Business Segments
- 10.2.5. Product Portfolio
- 10.2.6. Business Performance
- 10.2.7. Key Strategic Moves and Developments
- 10.3. Novo Nordisk A/S
- 10.3.1. Company Overview
- 10.3.2. Key Executives
- 10.3.3. Company Snapshot
- 10.3.4. Operating Business Segments
- 10.3.5. Product Portfolio
- 10.3.6. Business Performance
- 10.3.7. Key Strategic Moves and Developments
- 10.4. Pfizer
- 10.4.1. Company Overview
- 10.4.2. Key Executives
- 10.4.3. Company Snapshot
- 10.4.4. Operating Business Segments
- 10.4.5. Product Portfolio
- 10.4.6. Business Performance
- 10.4.7. Key Strategic Moves and Developments
- 10.5. Biocon
- 10.5.1. Company Overview
- 10.5.2. Key Executives
- 10.5.3. Company Snapshot
- 10.5.4. Operating Business Segments
- 10.5.5. Product Portfolio
- 10.5.6. Business Performance
- 10.5.7. Key Strategic Moves and Developments
- 10.6. Wockhardt
- 10.6.1. Company Overview
- 10.6.2. Key Executives
- 10.6.3. Company Snapshot
- 10.6.4. Operating Business Segments
- 10.6.5. Product Portfolio
- 10.6.6. Business Performance
- 10.6.7. Key Strategic Moves and Developments
- 10.7. MannKind Corporation
- 10.7.1. Company Overview
- 10.7.2. Key Executives
- 10.7.3. Company Snapshot
- 10.7.4. Operating Business Segments
- 10.7.5. Product Portfolio
- 10.7.6. Business Performance
- 10.7.7. Key Strategic Moves and Developments
- 10.8. Tonghua Dongbao Pharmaceutical Co., Ltd.
- 10.8.1. Company Overview
- 10.8.2. Key Executives
- 10.8.3. Company Snapshot
- 10.8.4. Operating Business Segments
- 10.8.5. Product Portfolio
- 10.8.6. Business Performance
- 10.8.7. Key Strategic Moves and Developments
- 10.9. Medtronic
- 10.9.1. Company Overview
- 10.9.2. Key Executives
- 10.9.3. Company Snapshot
- 10.9.4. Operating Business Segments
- 10.9.5. Product Portfolio
- 10.9.6. Business Performance
- 10.9.7. Key Strategic Moves and Developments
- 10.10. Lupin
- 10.10.1. Company Overview
- 10.10.2. Key Executives
- 10.10.3. Company Snapshot
- 10.10.4. Operating Business Segments
- 10.10.5. Product Portfolio
- 10.10.6. Business Performance
- 10.10.7. Key Strategic Moves and Developments
